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Addiction Biology. 2019;1–9.Abstract
When exposed to ethanol, Drosophila melanogaster display a variety of addiction‐like
behaviours similar to those observed in mammals. Sensitivity to ethanol can be quan-
tified by measuring the time at which 50% of the flies are sedated by ethanol expo-
sure (ST50); an increase of ST50 following multiple ethanol exposures is widely
interpreted as development of tolerance to ethanol. Sensitivity and tolerance to eth-
anol were measured after administration of the gamma‐aminobutyric acid receptor B
(GABAB) agonist (SKF 97541) and antagonist (CGP 54626), when compared with flies
treated with ethanol alone. Dose‐dependent increases and decreases in sensitivity to
ethanol were observed for both the agonist and antagonist respectively. Tolerance
was recorded in the presence of GABAB drugs, but the rate of tolerance development
was increased by SKF 97451 and unaltered in presence of CGP 54626. This indicates
that the GABAB receptor contributes to both the sensitivity to ethanol and mecha-
nisms by which tolerance develops. The data also reinforce the usefulness of Drosoph-
ila as a model for identifying the molecular components of addictive behaviours and
for testing drugs that could potentially be used for the treatment of alcohol use disor-
der (AUD).
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SKF 975411 | INTRODUCTION
Repeated alcohol consumption in humans leads to an increase in
tolerance to alcohol, a known alcohol‐associated behaviour that
can be replicated in animal models.1 Amongst the many pathways
and genes that have been identified in animal models as being
involved in initiating a change in alcohol‐associated behaviours, there
has been no single molecular pathway or gene that has been shown
to be solely responsible for reproducing or increasing tolerance and
sensitivity to ethanol.2- - - - - - - - - - - - - - - - - - - - - - - - - - -
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the mechanisms of alcohol use disorder (AUD).3-7 It is also specu-
lated that the GABAA receptor is responsible for acute alcohol
related changes in behaviour, but it is agreed amongst researchers
that more work needs to be done before conclusive statements
can be made.8 Less researched in the field of alcohol addiction when
compared with the GABAA receptor, is the gamma‐aminobutyric acid
receptor B (GABAB); a class C metabotropic G–protein‐coupled
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2 RANSON ET AL.promising role in altering the sensitivity and preference to alcohol
when pharmacologically targeted.9-13
The GABAB receptor has been investigated and pharmacologically
challenged with different GABAB receptor ligands in different animal
models for its potential role in modulating alcohol‐associated behav-
iours in AUD. Zaleski et al.,14 Cousins et al.,9 Dzitoyeva et al.,10 and
Hwa et al.,11 have all reported on the effects of administering a
GABAB receptor ligand to overcome the effects of alcohol addiction‐
like behaviours in both mammalian and invertebrate models. Likewise,
the pharmacological activation of the GABAB receptor has been
shown to reduce the behavioural effects of addiction to both cocaine
and nicotine.9,15,16 While these previous studies support the notion
that GABAB receptors play a role in addiction pathways, further inves-
tigations using GABAB receptor drugs have the potential to elucidate
the specific addiction mechanisms that are affected by GABAB
receptor activation or inhibition.
Among the wide variety of animal models employed in addiction
research, Drosophila melanogaster has been identified as being a strong
model for studying the acute and chronic effects of alcohol abuse.17-19
The underlying fundamental when using any animal model to replicate
a human disease is to ensure simplicity, reproducibility, and mechanis-
tic validity with respect to human behaviours, and Drosophila, in this
instance, are a highly valuable model when used to study alcohol
addiction‐like behaviours18,19.
In this work, GABAB receptor agonist, SKF 97541, and GABAB
receptor antagonist, CGP 54626, (previously used in Drosophila by
Dzitoyeva et al., Dacks et al., and Root et al.,10,21,22) were used to tar-
get the GABAB receptor to demonstrate that this receptor plays a role
in alcohol sensitivity and tolerance. This novel research supports the
possibility of targeting the GABAB receptor as a strategy for the treat-
ment of AUD.2 | MATERIALS AND METHODS
2.1 | Drosophila husbandry
All flies used were Canton S wild‐type male Drosophila (#64349)
obtained from Bloomington Drosophila Stock Centre, Indiana, USA.
Flies were kept at 25°C with an average humidity of 60% to 80% on
standard ready mixed dried food (Phillip Harris, UK). All flies tested
were aged 1 to 5‐day old (1‐day old on first day of testing) and were
collected the morning before testing via light CO2 anaesthesia to allow
sufficient recovery after sedation.2.2 | Tolerance assay
The tolerance assay was conducted by following the methodology
described by Maples and Rothenfluh.23 Male flies were sorted into
groups of eight and were placed into vials containing standard food
24 hours prior to testing. This was completed so that the group of
test flies could be transferred to the tolerance chamber with no
CO2 anaesthesia. Five hundred microliters of 100% ethanol were
added to the centre of a cotton vial plug, which was used to plug
the tolerance chamber with the ethanol soaked side facing inwards.Flies were left to be exposed to the ethanol vapour until 50% of the
total number of flies were sedated; this time point was defined as
ST50 (time taken for 50% of flies in the vial to become sedated).
Vials were tapped three times onto the lab bench once per minute
to disorientate and startle the flies and to knock them to the bottom
of the vial. Each vial was observed for 10 seconds, and the number
of stationary flies was recorded every minute. The term “sedation”
was determined by making clear distinguishable rules to follow; after
flies had been knocked to the bottom of the vial, any fly not able to
upright themselves within a 10 second observation time was deter-
mined as being sedated. Any leg movement or vibrating of the wings
was ignored, and if the flies were still upon their backs after being
startled to the bottom of the vial with the inability to self‐right,
the fly was also recorded as being sedated.
Each assay was conducted at room temperature (with a control
sample of eight 1‐ to 5‐day‐old male flies every time to ensure no bias
was created with a change in room temperature) until the ST50 for
each vial was achieved. Once sedated, flies were placed into an etha-
nol vapour free vial to recover at room temperature. After the flies had
recovered and normal motility had resumed, they were housed back
upon standard dry mix food at 25°C, and 24 hours later, the assay
was repeated.
Tolerance was measured over a period of 4 days, and the ST50
was recorded for each vial. Tolerance to ethanol is identified as being
an increase in ST50 over consecutive days following repeated ethanol
exposures. This results in flies having a decreased sensitivity to etha-
nol, consequently resulting in an increased ST50 over time when com-
pared with the first ethanol exposure on day one.23-26
Data from the tolerance assay were collected by testing one vial
of each condition on eight consecutive weeks. Each vial contained
eight 1 to 5‐day‐old male flies (1‐day old on first day of testing) per
vial. Mean values are N = 8 ± standard error of the mean (SEM).2.3 | Drug selection and delivery
SKF 97541 is a potent and selective GABAB receptor agonist, and
CGP 54626 is a potent and selective GABAB receptor antagonist
(Tocris Biotechne, UK). SKF 97451 was dissolved in water at a stock
concentration of 25 mM and CGP 54626 was dissolved in DMSO
(Tocris Biotechne, UK) at a stock concentration of 25 mM. Flies were
exposed to the drugs at the desired concentrations in the liquid food
(5% yeast extract, 5% sucrose, 1% red coloured dye [Sigma Aldrich,
UK]). Drug and control solutions were loaded into four 5 μL glass cap-
illaries (Jaytec, UK) within a CAFÉ assay chamber as described by Ja
et al.27 Flies were allowed to consume the liquid food via the four‐
glass capillaries for 24‐hour ad libitum. Flies' abdomens were observed
to see if they were red prior to testing; this was used as a positive indi-
cator as to whether the flies had consumed/recently consumed the
liquid food containing the red food colouring. The average consump-
tion of liquid food was estimated from measuring the capillary menis-
cus over 24 hours, and it was estimated to be 0.42 μL ± 0.046 SEM
with no significant difference in the consumption of different drug
containing foods (Figure S1). Vials with flies that had less than four
out of eight red abdomens were discarded. Control flies were fed
RANSON ET AL. 3the same liquid food with no added drug. A vehicle control group was
treated with 0.002% DMSO (Tocris Biotechne, UK) which corresponds
to the dose of DMSO delivered with CGP 54626. Liquid foods
with/without the drug were given to Drosophila with different
protocols: (a) for 24 hours prior and during the 4 days of tolerance
testing, (b) only for 24 hours prior to tolerance testing, (c) only for
24 hours after the second ethanol exposure, prior to the day 3
ethanol exposure (Figure 1).2.4 | Locomotor activity assay
The locomotor climbing assay was constructed by wrapping 2‐cm
graph paper with horizontal lines around the rear of a standard
9.5 × 2.5 cm vial (height × diameter). A vial was positioned in closeFIGURE 1 Administration schedule of ethanol and gamma‐
aminobutyric acid receptor B (GABAB) drugs. All flies were exposed
to ethanol vapour four times and their ST50 recorded (ST50 assay
1‐4). GABAB drugs were administered to the fly via liquid food
presented in capillary tubes to which the flies had access ad libitum.
Three different GABAB drug administration schedules were used: A,
continuous administration: flies were fed with the drug for 24 hours
before the first tolerance assay (when flies were naive to ethanol)
and throughout the period in between consequent ST50 assays, B,
preadministration: drugs were fed only for 24 hours before the first
ST50 assay (when flies were naive to ethanol), C, mid administration:
drugs were fed for 24 hours only between the second and third
ST50 assay. Each arrow represents drug administration for a 24‐hour
periodproximity to a timer, and a camera was positioned to capture both
the climbing assay vial and the timer within one frame. The camera
was set to record once the flies were transferred within the assay vial
and cameras field of view. All flies were then tapped to the bottom of
the vial and at the time of doing so, the timer was manually started.
The frames of video were visualised through QuickTime Player
Version 10.4 (Apple Inc, USA) by scanning through frame by frame
until all flies had crossed the 8 cm mark on the vial or 15 seconds
had elapsed, whichever was sooner. The time at which all flies had
crossed the 8‐cm mark was then recorded.2.5 | Ethanol concentration measurement
Ethanol absorption was measured with a spectrophotometric assay as
described previously by Moore et al.28 Thirty 1 to 5‐day‐old male flies
were exposed to 500 μL of 100% ethanol in a tolerance chamber (as
described above). After 30 minutes, flies were frozen in dry ice and
were homogenised in 300 μL of ice‐cold Tris‐HCl (pH 7.5). The
homogenate was centrifuged at 4500 revolutions per minute for
20 minutes at 4°C. Five microlitres of supernatant was added to
495 μL of ethanol assay reagent (Sigma, UK). The manufacturers
protocol and calculation instructions were followed. To calculate the
ethanol concentration in individual flies, the volume of one fly was
estimated to be 2 μL.28 The estimated ethanol concentration in one
individual fly after 30 minutes was calculated to be 6.5 mM. A control
group (no ethanol vapour) was also assayed, and this result was
negative (Figure S2).2.6 | Statistical analysis
All graphs and analysis were made and executed using the Prism for
Mac OS X Version 7.0 (GraphPad Software Inc, USA).
The change in sensitivity (in minutes) was calculated by
subtracting the ST50 value of the treated flies by the ST50 value for
the control flies of the same day of treatment. The percentage change
in sensitivity from day 2 to day 4 (tolerance) was calculated by the for-
mula ([(‘Day X’ ST50/Day 1 ST50] −1) × 100. ANOVA analysis was car-
ried out to determine statistical significance.3 | RESULTS
3.1 | Development of tolerance to ethanol
Repeated exposures to ethanol in wild type flies leads to a reduced
sensitivity to its sedative effect. Tolerance development is defined as
a change in the time (ST50) needed for half of a set of flies exposed
to ethanol vapour to become sedated as compared with the first eth-
anol exposure. ST50 was measured in sets of eight male flies and was
shown to increase over a period of 5 days with daily ethanol expo-
sures (Figure 2). These findings are consistent with previous reports
confirming that D. melanogaster are a suitable model to study the
development of alcohol tolerance as an addiction like behaviour, sim-
ilar to that seen in humans.20,23,24,26,29
FIGURE 2 Tolerance development in wild‐type Drosophila. The time
at which half of each group of flies were sedated (ST50) when
exposed to 500 μL of 100% EtOH was recorded for five consecutive
days. Flies were naive to ethanol prior to day 1. Values are
mean ± SEM with N = 8 (eight vials with eight flies per vial). 1‐way
ANOVA with Tukey vs previous day. Statistical comparison indicated
by lines. * = <0.05, ** = <0.01, **** = <0.0001
4 RANSON ET AL.3.2 | Tolerance development with continuous
administration of agonist SKF 97541
The GABAB receptor agonist SKF 97541 was dissolved in liquid food
and was administered via glass capillaries ad libitum for 24 hoursFIGURE 3 Effect of continuous administration of SKF 97451 on ST50. Fl
and for the whole period in between the four ethanol exposures. Horizon
concentration of SKF 97451 when compared with the control of the same
flies is indicated in minutes mean ± SEM at the zero‐difference point for e
control of that day. ** = <0.01, *** = <0.001, **** = <0.0001prior to the first ST50 assay and during the subsequent 3 days of
testing (Figure 1A for drug administration schedule). SKF 97541
agonist was effective at reducing ST50 and thus increasing the
sensitivity of the flies to ethanol (Figure 3). On each day of testing,
at all drug concentrations used, ST50 values expressed in minutes
were lower in the drug treated flies than in untreated control flies
by comparing values for the same day of exposure.
It can be observed that whilst SKF 97541 significantly reduces the
time in which sedation occurs by increasing the sensitivity of the flies
to the ethanol vapour, the flies do retain the ability to develop toler-
ance to ethanol as demonstrated by the ST50 percentage change
measured at each of the test days when compared with the first day
of exposure (Figure 4A). It should also be noted that tolerance devel-
opment was increased by SKF 97541 by the end of the 4‐day
exposure. The tolerance percentage change increased from 56.72%
(water control) on day 4, to 67.53%, 83.81%, 152.31% (SKF 97541:
25 μM, 250 μM, 1.25 mM). The 1.25 mM concentration induced
change that was statistically significant on day 3 and 4 (p <0.05,
p <0.001 respectively).3.3 | Tolerance development with continuous
administration of antagonist CGP 54626
To further explore the role of the GABAB receptor in response to eth-
anol exposure, the GABAB antagonist CGP 54626 was administered to
the flies with the same protocol used for the agonist (Figure 1A,
Figure 4B and Figure 5).ies were fed SKF 97451 for 24 hours before the first ethanol exposure
tal bars represent changes in ST50 in minutes in flies fed different
day. N = 8 (eight vials with eight flies per vial). The ST50 of the control
ach consecutive day. Averages ± SEM. 2‐way ANOVA with Tukey vs
FIGURE 4 Change in tolerance after continuous administration of SKF 97541 and CGP 54626. Flies were fed either with A, SKF 97541 or B,
CGP 54626 for 24 hours before the first ethanol exposure and for the whole period in between the four exposures. N = 8 (eight vials with
eight flies per vial). Averages ± SEM. 2‐way ANOVA. Significance reported is SKF 97541 1.25 mM vs water control * = <0.05, **** = <0.0001. The
percentage change in sensitivity (tolerance) was calculated by the formula ([‘Day X’ ST50/Day 1 ST50] − 1) × 100
FIGURE 5 Effect of continuous administration of CGP 54626 on ST50. Flies were fed with CGP 54626 for 24 hours before the first ethanol
exposure and for the whole period in between the four ethanol exposures. Horizontal bars represent changes in ST50 in minutes in flies fed
different concentration of CGP 54626 when compared with the control of the same day. N = 8 (eight vials with eight flies per vial). The ST50 of
the control flies is indicated in minutes ± SEM at the zero difference point for each consecutive day. Averages ± SEM. 2‐way ANOVA with Tukey
vs. control of that day. * = <0.05, ** = <0.01, *** = <0.001, **** = <0.0001
RANSON ET AL. 5Administration of CGP 54626 for 24 hours prior to day 1 of the
ST50 assay and continually administered for the following 3 days of
testing resulted in a significant decrease in sensitivity (increase in
ST50) at concentrations of 250 nM and 250 μM (Figure 5). The relative
increase in ST50 (tolerance development) occurred in the presence ofthe drug despite the already higher ST50 values. Thus, tolerance
development can occur in the presence of the agonist and antagonist
despite the fact that each drug reduced and increased ST50 values
respectively. However, unlike for SKF 97541 there was no significant
effect of CGP 54626 on the rate of tolerance development (Figure 4).
6 RANSON ET AL.3.4 | SKF 97541 agonist administration prior to and
during tolerance development
In order to investigate the continuity and stability on the effect of
the agonist SKF 97541, the drug was administered for just 24 hours
prior to the first tolerance assay (Figure 1B for administration
schedule and Figure 6).
SKF 97451 administered at concentrations of 25 μM, 250 μM,
and 1.25 mM before alcohol exposures significantly reduced ST50
when measured 24 and 48 hours after drug administration when
compared with untreated flies for the same day of ethanol exposure
(Figure 6A,B). On day 3 and 4, 72 and 96 hours after the initial drug
administration, only the 250 μM and 1.25 mM doses of agonist
remained effective at significantly reducing ST50 when compared
with the water control for that day (Figure 6C,D). Comparison of
Figure 6A and D indicates that the efficacy of the drug, when
administered prior to day 1, decreases over days in a dose‐
dependent manner. The ST50 percentage differences (not shown in
Figure 6) between day 1 and day 4 are 54.2%, 43.2%, and 30.7%
for control, 25 μM, 250 μM, and 1.25 mM respectively. The data
therefore indicates that the effect of SKF 97451 is dependent on
the drug being present at the time of the tolerance assay, and
although we have not measured drug kinetics, it appears that its
effect diminishes over time.
In order to further investigate whether SKF 97451 plays an active
role in tolerance behaviour development, flies were allowed to
develop tolerance to ethanol with two ethanol exposures over
48 hours, followed by 24 hours of ad libitum administration of SKF
97451. Flies were finally tested for tolerance over the next 48 hours
after drug administration (Figure 1C for administration schedule and
Figure 6). SKF 97451 concentrations of 25 μM, 250 μM, and 1.25
mM were able to significantly reduce the time to sedation values
when administered after two alcohol exposures (Figure 6C,D). This
highlights that the SKF 97541 agonist is effective at increasing the
flies sensitivity to ethanol both prior to the initial tolerance develop-
ment, and during the tolerance development when the flies sensitivity
has already been modified.3.5 | CGP 54626 antagonist administration prior to
and during tolerance development
Similarly to the experiments described above for SKF 97451, the
GABAB antagonist CGP 54626 was administered to the flies for
24 hours only prior to the four consecutive days of tolerance testing
or for 24 hours only after the second day of tolerance testing
(Figure 1B‐C for administration schedule). The 24‐hour administration
of CGP 54626 prior to tolerance testing was effective at increasing
the flies ST50 at a concentration of 250 μM on the first day of testing
(Figure 7A). Notably, on the second day of the tolerance assay, all
three concentrations tested (25 nM, 250 nM, and 250 μM) were sig-
nificantly effective at decreasing the sensitivity to ethanol, thus
increasing ST50 values when compared with the control for that
respective day (Figure 7B). The effect of the drug was diminished to
zero over the next 2 days of testing, and this indicates that the drugtakes more than 24 hours to reach full efficacy before starting to lose
its effect (Figure 7C‐D).
When CGP 54626 was administered after 2 days of ethanol
tolerance, the ST50 values were increased to highly significant values
when compared with the control for day 3 at all the CGP 54246
concentrations used, before slowly losing efficacy on day 4 (2 days/
48 hours after initial administration) and there being an evident
decrease in significance when compared with the control for day 4
in a dose dependent manner (Figure 7C,D).4 | DISCUSSION
Within this study, we have used a tolerance assay as described by
Maples and Rothenfluh23 to show that D. melanogaster can develop
tolerance with repeated exposures over consecutive days, mimicking
an alcohol‐related behaviour that is seen with AUDs in humans
(Figure 2). The Drosophila model allows pharmacological interventions
that can aid in dissecting the mechanisms of tolerance develop-
ment.23,24,26 In this work, we have used GABAB receptor ligands to
explore tolerance development. The range of concentrations of drug
used were determined by toxicity studies where flies survived for
more than 96 hours at the doses used (data not shown) and by
negative geotaxis assays to determine that the drugs did not cause
substantial effect on locomotor activity (Figure S3). The concentration
of 1.25 mM SKF 97451 did affect locomotor activity; however, the
results were retained in this study because it was of interest to
determine what effect this higher concentration had when the files
were exposed only for 24 hours pre or mid tolerance development
(Figure 6). Additionally, the fact that tolerance developed even after
continuous administration of this high concentration (Figure 3)
indicates that the effect on locomotor activity and ST50 measurement
is not necessarily correlated.
Whilst the idea that the GABAB receptor could be used as a
potential drug target to combat alcohol addiction like behaviours is
not novel,9-11,16,21 this study provides direct evidence of an agonist
and an antagonist ligand that are capable of increasing and decreasing
sensitivity to ethanol vapour respectively after different numbers of
alcohol exposures (Figures 3, 5–7).
The data presented indicate that the GABAB drugs affect the sen-
sitivity to alcohol by reducing/increasing the time to sedation, while
permitting tolerance development to occur (Figure 4A,B). It should
also be noted that the agonist SKF 97451 decreased the ST50 and
altered the rate at which tolerance (defined as an increase in ST50)
developed after four ethanol sensitivity assays. This novel data
reinforce the concept that the development of tolerance is a multifac-
torial process where GABAB receptors (like other receptor systems)
contribute to, but do not fully determine the development of toler-
ance. Whilst it is known that ethanol increases GABA release30 and
that the function of GABAA receptors is affected by ethanol,
3,8 it is
important to also fully characterise the role of GABAB receptors in
ethanol‐induced processes. The novel contribution of this work is that
the modulation of the GABAB receptors alters the sensitivity to etha-
nol as well as affecting the rate of tolerance development. There are
potentially different mechanisms by which modulation of the GABAB
FIGURE 6 Effect of SKF 97541 pre‐administration and mid‐administration on sedation time (ST50). Flies were fed with SKF 97451 only for
24 hours prior to the 4‐day tolerance assay (pre‐administration, white bars) or for 24 hours in between the second and third day of the 4‐day
tolerance assay (mid‐administration, shaded bars). Horizontal bars represent changes in ST50 in minutes in SKF 97451‐treated flies as compared
with control untreated flies for the same day of the tolerance assay. N = 8 (eight vials with eight flies per vial). The ST50 of the control flies is
indicated in minutes ± SEM at the zero‐difference point for each consecutive day. Averages ± SEM. 2‐way ANOVA with Tukey vs control of that
day. *** = <0.001, **** = <0.0001
FIGURE 7 Effect of CGP 54626 pre‐administration and mid‐administration on sedation time (ST50). Flies were fed with CGP 54626 only for
24 hours prior to the 4‐day tolerance assay (pre‐administration, white bars) or for 24 hours in between the second and third day of the 4‐day
tolerance assay (mid‐administration, shaded bars). Horizontal bars represent changes in ST50 in minutes in CGP 54626‐treated flies as compared
with control‐untreated flies for the same day of the tolerance assay. N = 8 (eight vials with eight flies per vial). The ST50 of the control flies is
indicated in minutes ± SEM at the zero‐difference point for each consecutive day. Averages ± SEM. 2‐way ANOVA with Tukey vs control of that
day. * = <0.05, ** = <0.01, *** = <0.001, **** = <0.0001
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include modulation of GABA or other neurotransmitter release in the
brain, and alcohol metabolism within the brain and other organs.
Prior to the successful cloning of the GABAB receptor subunits by
Mezler, Müller and Raming,31 Drosophila was thought to lack GABAB
receptors, as the GABAB receptor agonist Baclofen has been reported
to have no effect in Drosophila.13 However, the two pharmacological
probes (agonist SKF 97541 and antagonist CGP 54626) used
here have been reported to work as a specific GABAB receptor agonist
and antagonist in Drosophila.10,21,22 It still remains to be
established however, as to why baclofen does not appear to be
functional in Drosophila.
The ultimate goal of alcohol addiction research is to resolve
addiction‐like behaviours in individuals with AUD. This work has
strengthened the possibility that the GABAB receptor could be
pharmacologically targeted to improve AUD related behaviour.
However, further investigations on the role of GABAB receptors are
required. The Drosophila model and the vast genetic tools that have
been made available by the Drosophila research community have the
potential to identify pharmacological strategies that could then be
tested and applied in human subjects.
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